AMENDMENTS TO THE SPECIFICATION

(1) Please replace paragraph [0027] in its entirety with the following paragraph:

[0027] Preferably a wax suitable for use in a formulation according to the present invention can be selected from the group consisting of beeswax, shellac, carnauba wax, spermaceti, lanolin, jojoba oil, candellila wax, ozocerite, opaglosOpaglos® 6000 P and the like. Most preferred waxes for use in the coating of a formulation according to the present invention are carnauba wax, beeswax or opaglosOpaglos® 6000 P.

(2) Please replace paragraph [0049] in its entirety with the following paragraph:

[0049] The procedure described in Example 1 was repeated for the following ingredients.

Sr. No.	Ingredients	Quantity (mg/tablet)
1.	Sumatriptan succinate equivalent to sumatriptan	35.00
2.	Mannitol	30.25
3.	Croscarmellose sodium	3.00
4.	Hypromellose	2.00
5.	Purified water	q.s.
6.	Avicel PH112	5.00
7.	Magnesium Stearate	0.75
	Coating	
8.	OpaglossOpaglos® 6000 P	1.00
9.	Isopropyl alcohol	q.s.

(3) Please replace paragraph [0051] in its entirety with the following paragraph:

[0051] Sumatriptan succinate was mixed with DCP anhydrous. The remaining excipients were added to resulting drug mix, followed by lubricating with magnesium stearate and compressing in a suitable tooling. The resulting tablet cores were coated with opaglos® 6000 P.

Sr. No.	Ingredients	Quantity (mg/tablet)
1.	Sumatriptan succinate	140.00
2.	Dibasic calcium phosphate DCP anhydrous	86.70
3.	Croscarmellose sodium (Ac-di-sol)	24.00
4.	Sodium Carbonate	20.00
5.	Hydroxypropylmethylcellulose (3cps)	4.80
6.	Microcrystalline cellulose (Avicel pH112)	20.00
7.	Magnesium Stearate	4.50
8.	Opaglos@ 6000 P	4.00
9.	IPA	q.s.
	Total	300.00